PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsEpoetin delta
Epoetin delta
Dynepo (epoetin delta) is a protein pharmaceutical. Epoetin delta was first approved as Dynepo on 2002-03-18. It has been approved in Europe to treat anemia and chronic kidney failure.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
urogenital diseasesD000091642
hemic and lymphatic diseasesD006425
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
803 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AnemiaD000740EFO_0004272D64.9141161507872420
Kidney diseasesD007674EFO_0003086N08945492235157
Chronic renal insufficiencyD051436N181040522030151
Chronic kidney failureD007676EFO_0003884N18.682423141379
Renal insufficiencyD051437N197202414972
NeoplasmsD009369C801161651250
SyndromeD013577225113846
Myelodysplastic syndromesD009190D46324123745
PreleukemiaD011289223123643
Iron deficienciesD000090463E61.113461022
Show 72 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients1631523
LeukemiaD007938C9587116
Multiple myelomaD009101C90.038415
Wounds and injuriesD014947T14.8164514
Blood transfusionD00180345612
Plasma cell neoplasmsD05421936211
Brain injuriesD001930S06.975111
Brain diseasesD001927G93.4054511
Traumatic brain injuriesD000070642S065418
StrokeD020521EFO_0000712I63.93618
Show 103 more
Indications Phases 2
Indications Phases 1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
CytopeniaD00009554299
PancytopeniaD010198D61.8188
Iron metabolism disordersD019189E83.122
Hemolytic anemiaD000743D55-D5922
Surgical blood lossD01606322
Respiratory insufficiencyD012131J96.922
Type 1 diabetes mellitusD003922EFO_0001359E1022
Diabetic retinopathyD003930EFO_000377011
Continuous ambulatory peritoneal dialysisD01053111
Developmental disabilitiesD002658EFO_0003852F8911
Show 40 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameEpoetin delta
INNepoetin delta
Description
Dynepo (epoetin delta) is a protein pharmaceutical. Epoetin delta was first approved as Dynepo on 2002-03-18. It has been approved in Europe to treat anemia and chronic kidney failure.
Classification
Protein
Drug classerythropoietins
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB
CAS-ID
RxCUI
ChEMBL IDCHEMBL2109093
ChEBI ID
PubChem CID
DrugBank
UNII ID474EI5756Y (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 106 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
6 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use